In the phase III KEYNOTE-189 trial, patients with non-squamous NSCLC and a PDL-1 ≥ 50% and PDL-1 1–49% had a statistically significant PFS benefit (HR 0.35, 95% CI [0.25–0.49], and 0.53, 95% CI [0.38–0.74], respectively), while patients with PDL-1 < 1% had a less impressive benefit (HR 0.67, 95% CI [0.49–0.93]) [14]. Here, CD274 is linked to non-small cell lung carcinoma.